



Marksans Pharma Ltd.

Date: 30th June, 2025

BSE Limited

Corporate Relation Department
Phiroze Jeejeebhoi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

**Sub.: Receipt of EIR from USFDA for inspection conducted at manufacturing facility of
Company's subsidiary Time-Cap Laboratories, Inc.**

Dear Sirs,

This is in continuation to our letter dated 28th April 2025 about a current Good Manufacturing Practices (cGMP) inspection conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA ("the Subsidiary") from 16th April 2025 to 24th April 2025.

Please be informed that the Company's subsidiary Time-Cap Laboratories Inc. has received the Establishment Inspection Report from USFDA.

Please take the above information on record.

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma

Marksans Pharma Ltd. (www.marksanspharma.com) headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com
www.marksanspharma.com